clinical trial · NCT05700422
Nasal Spray Study in Sjogren's Dry Eye Disease
Sjogren's SyndromeDry EyeVarenicline Nasal Spray
brief summary
This study will investigate how well OC-01 (varenicline) nasal spray can treat the signs and symptoms of dry eye disease in those Sjogren's Syndrome. Patients at least 18 years old with moderate-to-severe Sjogren's dry eye disease may be eligible for this study. If you are eligible to participate in the study and you decide to join, there will be 3 study visits over approximately 1 month. You will also self-administer the nasal spray at home every day, 2 times a day during this month.
started
May 1, 2023
primary completion
Aug 31, 2023
completion
Aug 31, 2023
last updated
Nov 5, 2024
official title
A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects With Sjogren's Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol